Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LIBerate-OLE: Long-Term Efficacy and Safety of Lerodalcibep
NCT04798430Phase 3Enrolling by invitation
- Sponsor
- LIB Therapeutics
- Start
- Dec 2020
- Primary completion
- Jul 2025
- Modality
- Fc-Fusion Proteins
- Countries
- 6
01
Overview
A Phase 3 trial of lerodalcibep in familial hypercholesterolemia (FH), cardiovascular disease (CVD), hypercholesterolemia, sponsored by LIB Therapeutics. Started Dec 2020; status: enrolling by invitation.
02
Drugs
lerodalcibep
03
Conditions
familial hypercholesterolemia (FH)cardiovascular disease (CVD)hypercholesterolemia
Beyond the preview
Go deeper on NCT04798430.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04798430.